Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99


Any time

2019 ( 6 )

2018 ( 14 )

2017 ( 16 )

2016 ( 15 )

Custom range...

Search Results: 1 - 10 of 506 matches for " IMMUNOTHERAPY "
All listed articles are free for downloading (OA Articles)
Page 1 /506
Display every page Item
Opsoclonus-Myoclonus Syndrome Post-Vaccination and Viral Illness  [PDF]
Amanda L. Piquet, Milind Kothari, David Ermak, Aiesha Ahmed
International Journal of Clinical Medicine (IJCM) , 2012, DOI: 10.4236/ijcm.2012.34060
Abstract: Opsoclonus-myoclonus syndrome is a rare condition with dyskinesia of eye movements and myoclonic movements of the trunk and limbs. It is linked to malignancies, infections and other conditions. We present a case of post-vaccination opsoclonus-myoclonus syndrome. We believe that our patient also experienced a viral illness post-vaccination and prior to the development of opsoclonus-myoclonus. The vaccination in combination with the viral illness potentiated the immune mechanism thought to be noted in this condition. This was supported by her recovery after receiving immunotherapy.
Desensitization Efficacy by Sublingual Immunotherapy of Shrimps Extract in Asthmatic, Rhinitis and Urticaria Allergic Patients  [PDF]
Maged M. Refaat, Mohammed Yousef Attia, Howida Mohamed Saber
Food and Nutrition Sciences (FNS) , 2014, DOI: 10.4236/fns.2014.517183
Abstract: RATIONALE: Crustaceans, such as shrimp, crab, crayfish and lobster, play important role in human nutrition; they also can be important causes of severe acute hypersensitivity reactions. For patients diagnosed with a crustacean allergy, strict avoidance is the only proven therapy, highlighting the need for more specific treatment. Our aim was to evaluate the efficacy and tolerance of sublingual shrimp immunotherapy in Egyptian patients allergic to shrimp. METHODS: This study was intended to help in diagnosis of shrimps allergen in 60 allergic patients (subdivided to 3 groups Urticaria (G1), rhinitis (G2) & asthma (G3)) and evaluate the sublingual immunotherapy by employing skin prick test, specific Immunoglobulin E, Total Immunoglobulin E, Immunoglobulin G, Eosinophilis and Peak Expiratory Flow Rate (PEFR), before and after therapy. Inclusion criteria were a history of shrimp allergy and positive skin prick test to crude shrimp extract from two species [Penaeus semisulcatus and Metapenaeus stebbingi] at allergy and clinical immunology unit, in-Shams Hospitals. They underwent immunotherapy with extract of shrimp species and administered sublingually (SLIT). The measurement of all latter investigations for shrimp allergen on the start and 6 months after immunotherapy, as compared to placebo control, were performed. Results: The clinical response and laboratory improvement of the patients was correlated with their decline in the eosinophils (p < 0.001), total Immunoglobulin E (p < 0.001) and specific Immunoglobulin E test (p < 0.001) and with their increased in PEFR (p < 0.001) and Immunoglobulin G (p < 0.001). This study suggests that the most desenstized responsed group was rhinitis group followed by Urticaria group. Also,The more effective season induce allergy in summer (48.3%) followed by springs (28.3%) and genatic predisposition of allergic diseases was highly accepted in patients had a family history (68%). In conclusion, sublingual immunotherapy for shrimp allergy was safe, simple, uncostly, well tolerated and efficacious, gave a good results especially in the treatment of patients with allergic rhinitis.
Clinical Profile and Results in Cancers Treated with Nivolumab: A Single Centre Study  [PDF]
B. J. Srinivasa, Bhanu Prakash Lalkota, Sulav Sapkota, Vinu Sarathy, Nithin Bayas, Radheshyam Naik
Open Journal of Immunology (OJI) , 2018, DOI: 10.4236/oji.2018.84007
Abstract: Introduction: Immunotherapy is also called as biologic therapy or bio-therapy. Immunotherapy is quickly becoming an important component in the multipronged approaches being developed to treat certain forms of cancer. The goal of immunotherapy is to strengthen the body’s own natu-ral ability to combat cancer by enhancing the effectiveness of the immune system. This study tries to compile response rates and side effect profile of Nivolumab. Methods: Patients with performance status of 3 or less than 3, who failed on 2 or more lines of therapy except melanoma and have received minimum 3 cycles of Nivolumab were taken in to this study. Study subjects followed for minimum of 3 cycles for assessment. Each patient received 240 mg of Nivolumab once in 15 days for 3 - 6 cycles. Results: The median age of 20 patients was 53 years (26 - 79 yrs). 18 patients were male and 2 patients were female. Progressive disease (PD) was observed in 12 patients with immunotherapy treatment and partial response (PR) was observed in 3 patients, and stable disease (SD) in 5 patients. Conclusion: This is one of the Indian study mainly reporting experiences with Nivolumab. Large sample size is required to conclude about the efficacy of the study. Nivolumab is more tolerated in Indian patients compared to other reported studies.
Clinical Efficacy of Allergen Specific Immunotherapy (ASIT) in Allergic Rhinitis  [PDF]
Rao Sukhesh
International Journal of Clinical Medicine (IJCM) , 2011, DOI: 10.4236/ijcm.2011.24066
Abstract: Though efficacy of Allergen Specific Immunotherapy (ASIT) has been proved in many studies, reports about success in clinical practice and under field conditions in alleviating the suffering or decreasing the morbidity in patients of Allergic Rhinitis are few. 260 patients of Allergic Rhinitis without coexisting diseases were included. Skin prick test was done on all patients. ASIT was initiated with common inhalant indoor allergens as per standard protocol and patients were assessed at the start and at 2 m, 6 m and 18 months of ASIT. ASIT was able to significantly reduce the symptom score in all the three groups namely sneezing, rhinorrhoea and nasal itching (p < 0.001). Concurrently it was also able to produce a significant reduction in the usage of concomitant drug intake (p < 0.001) thereby implying a decrease in morbidity. When assessed regarding clinical efficacy, ASIT was found to be satisfactory or highly effective in more than 75% patients. ASIT has got a role in clinical practice in polysensitized patients in field conditions. This is based on the evidence that besides decrease in hypersensitivity/symptoms, it also has an effect on minimizing the necessity of taking drugs to relieve the symptoms, which has strong implications of economics and toxicity, while treating patients.
Efficacy of Oral Antigen Specific Immunotherapy on Desensitization of Some Autoimmune Diseases Associated with Milk Allergy  [PDF]
Azza A. Atef, Mohamed Y. Attia, Osama E. Abdel Aal
Food and Nutrition Sciences (FNS) , 2013, DOI: 10.4236/fns.2013.48104

There are several reports on the prevalence and importance of milk allergens in the induction of allergic diseases, whereas its role in the induction of autoimmune disease was rarely studied. So, the present work aimed to study the diagnosis and the efficacy of oral antigen specific immunotherapy (OAIT) on two groups of autoimmune disease patients namely, rheumatic arthritis (RA), group II, and systemic lupus erythematosus (SLE), group III, who has allergens for milk as an effective treatment option. From the assessment of the data obtained and the clinical outcome of RA and SLE patients after food elimination strategy and milk immunotherapy, it was evident that there were significant reductions (P < 0.001) in the levels of total IgE, specific IgE, Rheumatic factor (R.F), C-reactive protein (C.R.P), Anti-nuclear antibodies (ANA) and anti-double stranded DNA antibodies (Anti-ds DNA) compared to pretreated levels. Moreover, the immunotherapy induced “blocking antibodies” by remarkable highly significant increasing in IgG, phagocytic inhibition test (PIT %), Complement component 3(C3), and Complement component 4 (C4) levels. More improvement was noticed in the SLE as a result of the immunotherapy. Conclusion: milk desensitization is a gained interest and a safe valuable effective treatment of autoimmune conditions in Egypt.

Considerations for Combining High-Protease Extracts in Immunotherapy Vaccines  [PDF]
Carol M. Lilley, Donna J. Rekkerth, Brian F. Teske
Open Journal of Nursing (OJN) , 2014, DOI: 10.4236/ojn.2014.44029

Current practice parameters state that extracts rich in proteases, such as fungal and insect extracts, can be combined during preparation of allergy immunotherapy vaccines. However, until recently, this guideline has not been the subject of investigation. Scientists now have data that shed light on high-protease allergenic extract mixtures used in allergy immunotherapy. A study published in Annals of Allergy, Asthma & Immunology in 2012 reports on the compatibility of combining fungal and insect extracts and emphasizes the importance of understanding how protease activities and total glycerin levels in allergy extracts can affect the stability of allergy immunotherapy vaccine mixtures. This research provides a critical assessment of the mixing compatibilities of several well-characterized high-protease extracts and may influence future immunotherapy practice parameters and immunotherapy extract preparation guidelines.

Pathophysiological Justification for Allergen Immunotherapy in Food Allergy  [PDF]
Marta Che?mińska, Katarzyna Pu?niakowska
Food and Nutrition Sciences (FNS) , 2016, DOI: 10.4236/fns.2016.74031
Abstract: Apart from avoiding exposure, allergen immunotherapy (AI) is the only causal method of treating allergic diseases. The results of numerous studies have been published concerning the safety and effectiveness of the AI in treating allergic rhinitis, asthma or allergy to the venom of Hymenoptera insects. It has also been proven that administration of increasing preparation doses of allergen extractions alleviates the symptoms in patients after the exposure to some sensitizing allergens. The effect of the AI remains visible many years after completion of the therapy. Studies have been done in an attempt to employ specific immunotherapy in patients with food allergy symptoms. They have been mostly concerned with populations of patients suffering from allergy to the protein found in cow’s milk and hen eggs. It appears that a need arises to create a new therapeutic method for successful treatment of food allergies and specific allergen immunotherapy seems to be a promising step. Although still in its experimental phase, in many well documented cases the method allows for building patient’s tolerance towards small doses of sensitizing allergen and seems conducive to protecting the patient from anaphylactic reactions after incidental allergen consumption.
Inmunoterapia en melanoma
Torrella,A.; Noris-García,E.;
Oncología (Barcelona) , 2004, DOI: 10.4321/S0378-48352004000300002
Abstract: early surgery is the only method with demonstrated clinical effectiveness in the malignant melanoma treatment. the melanoma capacity to develop an effective immune response and its frequent resistance to chemotherapy and radiotherapy, lead to look for a therapeutic solution involving the immune system. currently a logarithmic increment of immunotherapy clinical trials in melanoma has been produced in its different modalities. although many of these immunotherapeutic agents have shown its efficacy, there are a lot of aspects to define for obtain a true effective and safe therapeutic strategy.
Inmunoterapia local
Lasa,E.; Garrido,S.; Arroabarren,E.; Anda,M.; Ollo,B.; Tabar,A.I.;
Anales del Sistema Sanitario de Navarra , 2003, DOI: 10.4321/S1137-66272003000400014
Abstract: specific immunotherapy, together with avoidance of the allergen and symptomatic treatment, forms part of the treatment of allergic pathology. the oldest, best known and most studied form is subcutaneous immunotherapy (scit), whose efficacy, both in the short and the long term, has been widely demonstrated in numerous studies. however, in spite of having been shown to be safe, it is not free of adverse effects and must be administered under the supervision of medical personnel. this has encouraged the search for new ways of administration of similar efficacy, with a good safety profile and good adherence on the patient?s side. sublingual immunotherapy (slit) is the most relevant of the different alternatives studied. in this alternative the antigen is administered in the form of drops under the tongue. there are different dosages of administration depending on the allergen involved. the optimum treatment dose has still to be determined, at present a wide range of dosages are found in comparison with subcutaneous immunotherapy. its mechanism of action is little known although immunological changes have been observed in different studies. slit has shown a good safety profile with scarce secondary effects, normally of a local character. similarly, different clinical tests have been carried out in which its efficacy has been shown in the treatment of respiratory allergy both in children and in adults. for this reason, although there are still unresolved data concerning this way of administering the immunotherapy, it has been proposed by the who as a valid alternative to scit.
Heat-Shocking of Murine Malignant Mesothelioma Cells Enhances Their Effectiveness as an Autologous Anti-Tumour Vaccine  [PDF]
Scott Fisher, Steve Broomfield, Robbert van Der Most, Richard Lake, Bruce Robinson, Andrew Currie
Journal of Cancer Therapy (JCT) , 2012, DOI: 10.4236/jct.2012.31007
Abstract: Background: Malignant mesothelioma (MM) is a highly aggressive, incurable asbestos-induced cancer for which treatment options are limited. Surgical resection can reduce tumour burden, but patients ultimately succumb to disease due to reoccurrence of unresectable tumour, highlighting the need for new treatment modalities. In this study we describe the use of an easily translatable heat shock (HS) treated autologous tumour lysate vaccine and discus its potential application as an adjunct therapy for treating MM. Methods: Heat shocked autologous tumour lysate (HSL) vaccine was generated from AE17sOVA mesothelioma cells and tested for its ability to act as a protective or therapeutic vaccine in a murine tumour model. Vaccine efficacy was assessed by tumour growth/survival of vaccinated mice and FACS analysis used to assess DC maturation and trafficking from vaccine site to draining lymphnodes (dLN). Results: Mice vaccinated prior to tumour challenge with HS lysate induced protection in 40% of mice and caused a significant delay in tumour progression in remaining mice. Vaccine dose-response experiments showed that HS lysate was at least a log more efficient at retarding tumour growth and promoting survival than untreated lysate. HS and untreated lysate were equally effective at maturating DCs, but HS lysate improved trafficking of vaccine-site DCs to draining lymph nodes (dLN). Direct intratumoural injection of HS lysate significantly delayed tumour progression. Conclusions: HS treatment of tumour lysate improved vaccine immunogenicity, was associated with DC maturation, increased DC trafficking to dLNs and delayed tumour growth, particularly when administered intratumourally. Heat shocking autologous tumour cells is a simple and easily translatable approach to generate an immunogenic lysate vaccine with significant prophylactic and therapeutic effects. Coupling intratumoural HS vaccines with conventional therapies such as surgery may improve patient responses for otherwise refractive tumours.
Page 1 /506
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.